Sellas Life Sciences Group Inc

Stock Chart, Company Information, and Scan Results

$4.88(as of Apr 27, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Sellas Life Sciences Group Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$4.88
Ticker SymbolSLS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees13
CountyUSA
Market Cap$823.0M

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Sellas Life Sciences Group Inc In Our Stock Scanner

As of Apr 28, 2026
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.